In8bio (INAB) Fundamental Analysis: Revenue, Earnings & Valuation

8.36 / 10

Outperform

Fundamental rating is Outperform with an 8.4/10 score. Key drivers—high accounts receivable turnover, strong interest coverage, and superior Asset‑MV, PB‑ROE, Revenue‑MV—push the composite fund score to 8.36. Overall fundamentals are exceptionally strong.

Analysis Checks(8/10)

Revenue-MV

Value-0.08

Score3/3

Weight27.84%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value134.75

Score2/3

Weight1.48%

1M Return0.58%

Inventory turnover ratio

Value106.57

Score3/3

Weight-1.58%

1M Return-0.67%

Accounts receivable turnover ratio

Value23.61

Score2/3

Weight-1.57%

1M Return-0.65%

PB-ROE

Value4.82

Score3/3

Weight40.27%

1M Return12.56%

Income tax / Total profit (%)

Value22.35

Score0/3

Weight-3.56%

1M Return-1.54%

Fixed assets turnover ratio

Value9771.06

Score1/3

Weight-2.93%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-1.77%

1M Return-0.73%

Cost of sales ratio (%)

Value57.03

Score2/3

Weight-1.73%

1M Return-0.74%

Asset-MV

Value-0.55

Score3/3

Weight43.55%

1M Return13.09%

Is INAB fundamentally strong?

INAB scores 8.36/10 on fundamentals and holds a Discounted valuation at present. Backed by its -92.49% ROE, 0.00% net margin, -0.79 P/E ratio, 0.55 P/B ratio, and 73.96% earnings growth, these metrics solidify its Outperform investment rating.